MORE►
Fortune 100
Almaden Genomics Chief Scientific Officer Mark Kunitomi (left) and Almaden's Executive Chairperson Tricia D’Cruz [Photos: Almaden Genomics]
Catalyze Dallas Launches New Portfolio Company to ‘Democratize and Accelerate Bioinformatics’
by Kevin Cummings | Oct 25, 2022
The Dallas-based venture development firm—which specializes in the commercialization of technology it acquires from Fortune 100 companies—has launched Almaden Genomics, a company with a newly released platform designed to streamline genomic workflows. Formerly part of IBM Research before its acquisition by Catalyze Dallas, Almaden calls its g.nome platform "a revolutionary approach to bioinformatics."
“The possibilities for the healthcare innovation it can power are as vast as they are life-changing," says Mark Kunitomi, Almaden's chief scientific officer.
